Amgen To Acquire Five Prime Therapeutics - Quick Facts

Amgen (AMGN) has agreed to acquire Five Prime Therapeutics (FPRX) for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The acquisition includes Bemarituzumab, a phase 3 ready, first-in-class program for Gastric Cancer.

Five Prime's lead asset, bemarituzumab, is a anti-FGFR2b antibody with positive data from a randomized, placebo-controlled phase 2 study in frontline advanced gastric or gastroesophageal junction cancer.

Amgen reaffirmed its full-year outlook with revenue guidance of $25.8 to $26.6 billion and non-GAAP EPS guidance of $16.00-$17.00.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Generative artificial intelligence or AI technologies, including the highly popular ChatGPT, could expose around 300 million full-time jobs around the world to automation, a report by Goldman Sachs predicts, deepening the rising fears about job security. According to a new research report by GS economists, "The Potentially Large Effects of Artificial Intelligence on Economic Growth",.. UBS Group AG has called back its former Chief Executive Officer Sergio Ermotti to lead the Swiss banking giant amid the new challenges and priorities it faces following its planned acquisition of troubled domestic rival Credit Suisse Group AG. Following the news, UBS shares were gaining more than 2 percent in Swiss trading as well as in pre-market activity on the NYSE. Canton, South Dakota-based Jarman's Midwest Cleaning Systems, Inc. is recalling certain hand sanitizer non-sterile solution due to the presence of methanol, the U.S. Food and Drug Administration said. The recall includes all lots of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution and Isopropyl Alcohol Antiseptic 75% Topical Solution Hand Sanitizer Non-sterile Solution
Follow RTT